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Implication for health policy/practice/research/medical education:
In this study we found that weekly vitamin D supplementation (cholecalciferol; 50,000 units for 12 weeks) had beneficial effect on HbA1c of 
male type 2 diabetic patients. Thus, oral vitamin D may help in improvement of glycemic control in these patients.
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Introduction
Diabetes mellitus is one of the most common metabolic 
diseases in the whole world. Over 150 million people are 
diagnosed with this disease worldwide and it is predicted that 
this number will reach to over 300 million people by 2025 (1). 
Vitamin D is a fat soluble vitamin which was discovered and 
named calciferol in 1930. In fact this vitamin is a hormonal 
precursor which its end product is built up inside the body 
(1,2). Apart from the crucial role of this vitamin in bones, this 
vitamin plays an essential role in autoimmune disorders as well 
as preventing colorectal, breast and prostatic cancer through 
preventing cell proliferation (3). Although 1,25(OH)2 vitamin 
D3 is important in calcium homeostasis, several investigations 
have revealed the effect of this vitamin on function of the 
immune system and also type 1 and type 2 diabetes mellitus 
(T2DM) (4). Studies have revealed the association between 
vitamin D deficiency and changes in blood glucose and insulin 
levels as well as sensitivity of the target tissues to insulin (5,6). 
This vitamin has many functions in the body and its receptors 
are present in over 30 different tissues such as pancreas, heart 
and lymphocytes (4-6). Vitamin D might help controlling 
diabetes mellitus through increasing insulin secretions and 
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Introduction: Studies have revealed the association between vitamin D deficiency and changes in blood 
glucose and insulin levels as well as sensitivity of the target tissues to insulin.
Objective: In this study, we examined the effect of adding vitamin D (cholecalciferol ; 50,000 units)  to 
therapeutic regimen of T2DM patients compared to placebo on regulating the blood glucose and glycemic 
parameters.
Patients and Methods: This study was a double blind clinical trial conducted on 60 type 2 diabetes mellitus 
(T2DM) patients. Exclusion criteria were taking calcium, vitamin D supplements or any drugs effecting 
calcium and vitamin D metabolism in the past 6 months. Serum 25-Hydroxy vitamin D [25(OH)D] 
level was measured with ELISA method. Patients were administered weekly vitamin D supplementation 
(50000 units) for 12 weeks.
Results: There was no significant relation between HbA1c and 25(OH)D level prior the study (p> 0.05). 
After intervention, 25(OH)D level in interventional group was significantly higher compared to that of 
control group. HbA1c in male interventional group was significantly less than that of control group (p= 
0.0068).  
Conclusion: Weekly vitamin D supplementation had beneficial effect on glycemic parameters in male 
type 2 diabetic patients. 
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increasing sensitivity to this hormone (4-6). Several researches 
have evaluated the association between vitamin D deficiency 
and glucose intolerance prevalence of T2DM. Various studies 
have shown a negative association between serum vitamin D 
level and glucose intolerance, while some others have not found 
any correlation (7). Only a few studies have assessed the effect 
of vitamin D on changes in blood glucose levels and insulin 
sensitivity, reporting controversial results (7-10). Many studies 
have demonstrated positive effect of vitamin D supplements on 
controlling hyperglycemia in diabetic patients. However, these 
studies are mainly conducted on animals (8-11). Studies on rats 
have revealed the direct effect of vitamin D on insulin secretion 
(6-12). Yet, the results of precisely designed randomized double 
blind controlled trials are not consistent with this finding (10-
13). 
Various studies have demonstrated the presence of 1-α 
hydroxylase and vitamin D receptors (VDR) on beta cells of 
pancreas. This enzyme converts 25(OH)D to 1, 25(OH)2 D3 
(7-13). These findings suggest the possible effect of vitamin 
D on glucose homeostasis (10-16). Therefore, if the beneficial 
effect of vitamin D therapy on controlling diabetes is approved, 
it could be used as an adjunct therapy in treating diabetes. 
Furthermore, it is revealed that vitamin D deficiency, even in 
developed countries is more than what predicted (12-17).
Objectives
In this study, we examined the effect of adding vitamin D to 
therapeutic regimen of T2DM patients compared to placebo on 
regulating the blood glucose and glycemic parameters.
Patients and Methods
Patients
This study was a randomized, double-blind, placebo controlled 
clinical trial on 60 patients diagnosed with T2DM referred 
to endocrinology clinic of Shahrekord University of Medical 
Sciences in 2011. The patients by computer-generated randomly 
permutated codes (prepared by WHO/Geneva) were allocated 
into two equal groups of 30.  The inclusion criteria were definite 
diagnosis of T2DM according to standard criteria, no renal or 
hepatic disease or any other chronic illness based on history 
and physical examinations. Exclusion criteria were taking 
calcium, vitamin D supplements or any drugs effecting calcium 
and vitamin D metabolism in the past 6 months.
Laboratory tests
First, the blood level of 25-Hydroxy vitamin D [25(OH)D] was 
measured in all the patients. One group received oral vitamin 
D (cholecalciferol), 50000 units per week for 12 weeks, while 
the other group received placebo for the same period of time. 
In all patients, fasting blood sugar (FBS), blood sugar (BS), 
2 hour postprandial blood sugar (2-hpp) and HbA1c were 
measured before and after drug therapy. Serum 25(OH)D was 
measured with ELISA method with sensitivity of 5 nol/L (2 ng/
ml) and specificity of 100 percent by Stat fax 2100 produced by 
Awareness Company (The United States). Serum 25(OH)D of 
below 50 nmol/L was considered deficient, between 50 and 70 
nmol/L insufficient, between 75 and 250 nmol/L sufficient and 
over 250 nmol/L potential intoxication. HbA1c was measured 
using column chromatography method with Nyco card reader 
II made in Norway. FBS, 2-hpp, BS were measured using 
spectrophotometer by Erba-XL 300 made in Germany.
Ethical issues
The research followed the tenets of the Declaration of Helsinki. 
Written informed consent was obtained from all patients. 
This study was approved by Ethical Committee of Shahrekord 
University of Medical Science. This study was registered in 
Iranian Registry of Clinical Trials (IRCT) and achieved the 
code of IRCT201011185191N6, too.
Statistical analysis
The data was analyzed with Stata software version 12 (Stata 
Corp, College Station, Tex) using student t-test, paired t-test, 
Pearson correlation and Chi square tests. P values of less than 
0.05 was assumed to be significant (p<0.05). 
Results
A total number of 60 type 2 diabetic patients were randomly 
assigned into two groups of intervention and control, each 
group consisting of 30 patients. The intervention group received 
vitamin D and the control group received placebo. The age of 
the patients ranged from 34 to 76 with the mean (SD) age of 55 
(10.7) years. There was not significant difference of age between 
groups (p= 0.88). Seventeen patients (28.3%) were male. The 
female to male ratio was not statistically significant (p= 0.58). 
Five patients had vitamin D deficiency (8.3%), 27 (45%)  had 
insufficient levels of vitamin D and in 28 (45%) patients vitamin 
D levels were within normal limits. None of the patients had 
vitamin D intoxication. There was no significant relation 
between HbA1c and 25(OH)D level prior the study (p=0.379). 
Table 1 demonstrates the laboratory parameters of both groups 
before and after the intervention. After intervention, 25 (OH)D 
Table 1. Mean (SD) of HbA1C and 25(OH)D and other laboratory parameters in relation to sex
Time of measurement Intervention Group Control Group Comparison Between Group P value*
Group beforeMean (SD)
after
Mean (SD) P value
before
Mean (SD)
after
Mean (SD) P value Interventional Control
HbA1c 
Male 7.67 (0.5) 6.78 (0.9) 0.0068* 7.41 (0.4) 6.97 (0.7) 0.22 0.019* 0.214
Female 7.65 (0.4) 7.45 (1.3) 0.52 7.68 (0.5) 7.67 (1) 0.95 0.53 0.959
Total 7.65 (0.4) 7.62 (0.52) 0.799 7.22 (1.2) 7.51 (1) 0.349 0.071 0.551
25(OH)D 
(nmol/L)
Male 82.5 (49) 167.8 (32) 0.001* 93.3 (67) 94.5 (55) 0.83 0.002* 0.971
Female 84.6 (54) 162.2 (67) 0.001* 109.5 (64) 122.2 (103) 0.4 0.003* 0.619
Total 83.9 (52) 164 (57) 0.001* 105.7 (64) 115.8 (94) 0.39 0.001* 0.632
*P <0.05 comparing the data of each group before and after intervention
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level in interventional group was significantly higher compared 
to that of control group.  HbA1c serum value of male diabetic 
patients in interventional group was less than that of control 
group (p=0.0068). 
Discussion
In this study, we found that serum HbA1c value was significantly 
less than that of control group in male interventional group. It 
means that, vitamin D therapy has had beneficial effect on the 
control of blood sugar in male diabetic patients. Vitamin D has 
evolved widespread interest in the pathogenesis and prevention 
of diabetes. Various prospective cohort investigations have 
shown that serum vitamin D level is inversely related to risk 
of T2DM (18). Sadek et al. conducted a study to evaluate the 
potential therapeutic efficacy of Vitamin D in preventing the 
detrimental effects of both types of diabetes mellitus, on 50 
male Wistar rats. They found that, Vitamin D improved the 
deleterious biochemical impact of diabetes mellitus, likely by 
increasing insulin secretion and sensitivity, improving the β-cell 
function, and decreasing the number of pro-inflammatory 
cytokines and insulin resistance (19). Altered expression of 
glucose transporters is a major characteristic of diabetes (12-
16). Tamilselvan et al., aimed to investigate the effect of vitamin 
D in the overall regulation of muscle cell glucose transporter 
expression. Treatment of myoblasts with 10-7 M calcitriol for 
24 h showed a significant increase in glucose transporter type 
1 (GLUT1), GLUT4, vitamin D receptor (VDR), and insulin 
receptor expression in type 1 and 2 diabetic model compared 
to control group. The results showed a potential anti-diabetic 
function of vitamin D on GLUT4, VDR, GLUT1 and insulin 
receptor by improving receptor gene expression suggesting a 
role for vitamin D in regulation of expression of the glucose 
transporters in muscle cells (20). To assess the relationship 
between 25 (OH) vitamin D level and microvascular 
complications in patients with T2DM, 136 patients were 
enrolled in the cross-sectional study of Ahmadieh et al. They 
found, serum 25 (OH) vitamin D correlated negatively with 
HbA1c. They concluded that, low 25 (OH) vitamin D level was 
an independent predictor of HbA1c, diabetic neuropathy, and 
diabetic retinopathy in patients with T2DM (21). However, Tai 
et al. found that in short term, correcting of vitamin D level had 
no significant impact on blood glucose level, plasma insulin, 
insulin sensitivity or oral glucose tolerance test in vitamin D 
deficient patients who had not diabetes (10). Iyengar et al. 
measured fasting blood glucose level, C peptide and insulin as 
well as 2 hours blood sugar after 75 gram oral glucose intake 
in a Hispanic-American and Angolan population in order to 
assess the role of vitamin D binding globulin on regulating 
blood glucose level. The study showed a significant positive 
correlation between fasting blood sugar and vitamin D binding 
peptide genotype (22). Hossein-Nezhad et al. evaluated 741 
pregnant women in a cross-sectional survey. They found, a 
significant association between insulin resistance index and 
insulin sensitivity index with serum vitamin D level (after 
adjusting for BMI) (23). Additionally, active form of vitamin 
D is a protective factor against type 1 diabetic none-obese 
rats, which was found in the study of Giulietti et al. They also 
showed that incidence of type1 DM was higher in none-obese 
rats which were exposed to vitamin D deficiency in their early 
life (24). Likewise, Champe et al. found a negative association 
between serum vitamin D levels and fasting blood glucose 
and postprandial glucose levels too (25). As seen above, most 
researches indicating the impact of serum vitamin D level and 
blood glucose and insulin resistance are either experimental 
or cross-sectional epidemiologic studies or on non-diabetic 
patients. 
Conclusion
In our study, on 60 type 2 diabetes patients, who were randomly 
assigned into two equal groups of intervention and control, we 
found that weekly vitamin D supplementation (50000 units 
for 12 weeks) had beneficial effect on HbA1c of male type 2 
diabetes mellitus patients. However studies with larger sample 
size and longer duration of intervention or higher dosage of 
vitamin D supplements suggests. 
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